New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2013
09:19 EDTALU, CUK, LCC, ING, CCL, CPWR, ARIAOn The Fly: Pre-market Movers
HIGHER: Alcatel-Lucent (ALU), up 9.4% following upgraded to Buy at Deutsche Bank... ING Group (ING), up 3.6% after upgrade at BNP Paribas... ARIAD (ARIA), up 6.5% after updating on R&D and commercial progress for a newly launched drug and one under development... Navidea Biopharmaceuticals (NAVB), up 7.8% after its Lymphoseek meets primary efficacy endpoint in trial... LOWER: Compuware (CPWR), down 2.1%, after warning its fourth quarter earnings and revenue are likely to sharply miss consensus estimates... US Airways (LCC), down 1.8% following downgrade to Neutral from Buy at Bank of America Merrill Lynch... Carnival (CCL), down 1.7% after its "Triumph" cruiseship reported to have broken loose from its dock in Alabama.
News For CPWR;LCC;ALU;CCL;CUK;ARIA;ING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 19, 2014
05:41 EDTCCLCarnival announces two new ship orders with Fincantieri
Subscribe for More Information
December 18, 2014
15:21 EDTCCLNotable companies reporting before tomorrow's open
Subscribe for More Information
09:14 EDTCCLCruise sector won't benefit from Cuba deal for several years, says Wells Fargo
Subscribe for More Information
08:30 EDTALUAlcatel-Lucent, Nokia reported to be in merger talks, Bloomberg says
Subscribe for More Information
06:52 EDTCCLCarnival December volatility elevated into Q4 results and booking outlook
Subscribe for More Information
December 17, 2014
16:27 EDTCCLOn The Fly: Closing Wrap
Subscribe for More Information
12:57 EDTCCLOn The Fly: Midday Wrap
Subscribe for More Information
12:40 EDTINGING Groep upgraded to Outperform from Neutral at Macquarie
Subscribe for More Information
12:17 EDTCCLEasing of Cuba restrictions pushes number of stocks higher
Subscribe for More Information
December 14, 2014
18:45 EDTCCLCarnival, Royal Caribbean could climb 20%, Barron's says
Subscribe for More Information
December 11, 2014
13:40 EDTINGEuro zone banks accepted $160B in low interest loans, NY Times says
Subscribe for More Information
10:13 EDTARIAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
09:16 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTARIAARIAD downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded ARIAD to Underperform from Neutral. The firm said Iclusig launch metrics are weak and expects it to remain a last option for CML patients with specific resistant mutations or failure with other therapies. Price target lowered to $6 from $8.
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 9, 2014
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
December 8, 2014
16:18 EDTCPWRCompuware shareholders approve acquisition by Thoma Bravo
Compuware announced that at the special meeting of Compuware shareholders held earlier, shareholders voted to approve the proposed definitive merger agreement with Thoma Bravo. The transaction follows a thorough review by the Compuware Board of Directors of strategic options for Compuware. More than 99% of the shares voting at the special meeting voted in favor of the adoption of the merger agreement. The CEO of Compuware, Bob Paul, stated, “The acquisition by Thoma Bravo provides a great value proposition for Compuware’s shareholders and we are very pleased with the level of support this transaction has received from our shareholders.” Upon completion of the merger, valued at approximately $2.4B, Compuware shareholders will have received an aggregate value of $10.75 per share for each share of Compuware common stock they own as of the effective time of the merger, which includes a net cash payment of $10.389188 per share of common stock as well as the per-share value of the Covisint shares distributed to holders of Compuware equity as of October 20, the record date for the Covisint spin-off. The companies currently expect the merger to be completed later this month, following the satisfaction or waiver of all conditions to the merger.
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use